U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. E19 OPTIMISATION OF SAFETY DATA COLLECTION
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

E19 OPTIMISATION OF SAFETY DATA COLLECTION June 2019

Download the Draft Guidance Document Read the Federal Register Notice
Draft Level 1 Guidance

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2019-D-1828
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This Guideline is intended to provide internationally harmonised guidance on when it would be appropriate to use a selective approach to safety data collection in some late-stage pre-marketing or post- marketing studies, and how such an approach would be implemented. By collecting selective safety data,  the burden to patients would be reduced, a larger number of informative clinical studies could be carried  out with greater efficiency, studies could be conducted with greater global participation, and the public  health would be better served.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2019-D-1828.

Back to Top